ADC Deals Are Up 733% in 2026 — Here's the Data

Twenty-five ADC licensing deals closed between March 22 and September 22, 2026 — up 733% from just 3 deals in the prior six-month window. This is not a gradual uptick. This is a land grab. Big Pharma is filling pipeline gaps left by LOE exposure and clinical disappointments in other modalities, and ADC developers with differentiated payloads, novel linkers, or validated tumor targets are commanding premium economics as a result.

The Data — ADC Deal Activity, Period over Period

The numbers are unambiguous. ADC licensing activity in 2026 has exploded relative to the preceding period:

Three deals in six months is borderline dormant for a modality that generated $11B+ in global revenue in 2025. Twenty-five in the next six months signals a structural shift in how pharma is allocating capital. For context, Deal Benchmarks across all modalities rarely show period-over-period increases above 100%. A 733% swing is an outlier — and outliers demand explanation.

What's Driving the Trend

Three forces are converging. First, clinical validation has reached a tipping point. The success of next-generation ADCs targeting HER2-low, Trop-2, FRα, Nectin-4, and CLDN18.2 across solid tumor indications has expanded the addressable market for ADC therapeutics far beyond the original HER2+ breast cancer paradigm. Pharma BD teams no longer debate whether ADCs work — they debate which targets and tumor types remain underpenetrated. That confidence unlocks budgets.

Second, the competitive landscape is accelerating deal timelines. GSK has executed two major ADC licensing deals in 2026 alone (HUTCHMED and Hansoh). Genentech has signed two in the same week. When your direct competitor closes an ADC deal, the pressure to respond is immediate — especially when the most differentiated assets are finite. This is a classic "fear of missing out" cycle, and it compresses diligence timelines and inflates valuations. BD teams that waited through Q4 2025 and Q1 2026 are now paying the premium of inaction.

Third, manufacturing maturity has de-risked the modality. The CMC complexity that historically deterred some acquirers has been partially resolved by CDMOs scaling ADC-specific capacity and by platform companies standardizing conjugation chemistry. The result: pharma buyers are more comfortable underwriting late-stage development risk in ADCs than they were 18 months ago, which lowers the internal hurdle rate for BD committees and accelerates deal approvals.

Notable Deals

The top deals from this period reveal clear patterns in deal structure and strategic intent:

GSK's dual-deal strategy stands out. The Hansoh deal ($185M upfront, $1.7B TDV) is the largest disclosed ADC transaction of 2026, signaling GSK's willingness to pay top dollar for clinical-stage assets with differentiated targets. The HUTCHMED deal, at $110M upfront and $1.295B TDV, followed two months later. GSK is clearly building an ADC franchise, not placing a single bet. For biotech founders negotiating with GSK, this context matters: the company is a motivated, repeat buyer, which strengthens the seller's hand on deal terms.

Genentech's back-to-back signings with DualityBio and Innovent Biologics on the same day are notable for a different reason. Financial terms remain undisclosed, but the signal is strategic: Roche/Genentech — already a major player through the Daiichi Sankyo partnership — is expanding its ADC pipeline beyond existing collaborations. When a company with Enhertu on its roster keeps buying, it tells you the market is far from saturated.

Mersana's $40M upfront with J&J is a critical data point for earlier-stage ADC companies. Mersana's platform — centered on its Dolasynthen technology — was rewarded despite the company's history of clinical setbacks. The deal validates that differentiated ADC platform technology still commands licensing economics even when the clinical track record is mixed, provided the underlying science addresses a clear unmet need.

What This Means for BD Teams Right Now

This is a seller's market for ADC assets — full stop. If you are a biotech with a clinical or late-preclinical ADC program and you are not in active partnering discussions, you are leaving value on the table. The data supports that conclusion: 25 deals in 6 months means multiple pharma buyers are competing for a finite pool of quality assets. That competition drives upfronts higher, improves milestone structures, and gives licensors leverage on opt-in rights, territory splits, and co-promote provisions.

For buyers, the tactical calculus is different. Waiting is expensive. The Hansoh deal at $185M upfront is a benchmark that future licensors will reference in every term sheet negotiation. If you identified a target ADC asset in Q1 2026 and delayed, expect to pay 20–40% more today on upfront consideration alone. Use Solidus to benchmark your proposed terms against the current market and quantify where you stand relative to recent comps.

Deal structures are also evolving. We are seeing a shift toward higher upfronts as a percentage of TDV — licensors are demanding more cash at signing to de-risk their own runway and reduce dilution. Milestone-heavy structures with back-loaded economics are losing favor with biotech boards who have seen too many deals where regulatory milestones never trigger. If you're a buyer offering $20M upfront on a $1B TDV, expect pushback. The market has moved.

Territory-specific deals are another emerging pattern. Several of the undisclosed transactions in this 25-deal dataset involve ex-China or ex-Greater China rights, reflecting the maturation of Chinese ADC developers who retain domestic commercialization rights while partnering globally. BD teams should model territory-split structures carefully — the economics differ materially from global exclusive licenses, and royalty step-downs on retained territories can create misaligned incentives post-launch.

Benchmark your deal against current market rates. Whether you are structuring an ADC out-license or evaluating an inbound opportunity, the terms you negotiate today will be measured against this 2026 dataset. Use the Ambrosia calculator to stress-test your upfront, milestones, and royalty tiers against real transaction comps — and walk into your next negotiation with data, not assumptions.